Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADAPNASDAQ:AUTLNASDAQ:HARPNASDAQ:PDLINASDAQ:TCRR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.98+8.9%$1.40$0.42▼$2.05$971.05M2.391.81 million shs1.48 million shsAUTLAutolus Therapeutics$4.52-5.8%$5.89$1.61▼$7.45$1.20B1.91.51 million shs1.41 million shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/APDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/ATCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-8.98%-30.36%-36.28%+27.87%-40.50%AUTLAutolus Therapeutics-0.83%-9.94%-22.58%-21.44%+159.46%HARPHarpoon Therapeutics0.00%0.00%0.00%+2.22%+265.24%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%-14.94%Secret Bull Market Starts in This Unusual Sector (Ad)"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics0.9967 of 5 stars2.53.00.00.02.50.80.6AUTLAutolus Therapeutics2.8947 of 5 stars3.43.00.00.03.03.30.6HARPHarpoon Therapeutics1.5216 of 5 stars2.20.00.04.71.44.20.0PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics1.00Sell$2.50155.96% UpsideAUTLAutolus Therapeutics2.80Moderate Buy$8.1680.53% UpsideHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsidePDLIPDL BioPharmaN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest TCRR, PDLI, AUTL, ADAP, and HARP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/9/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $11.003/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/18/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.003/14/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.002/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.002/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.001/22/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$60.28M16.11N/AN/A$0.04 per share24.42AUTLAutolus Therapeutics$1.70M707.06N/AN/A$0.64 per share7.06HARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.55N/AN/AN/A-188.90%-155.39%-43.42%5/10/2024 (Estimated)AUTLAutolus Therapeutics-$208.38M-$1.19N/AN/AN/AN/A-105.75%-49.25%5/2/2024 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/APDLIPDL BioPharmaN/AN/A0.00∞N/AN/AN/AN/AN/ATCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest TCRR, PDLI, AUTL, ADAP, and HARP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023AUTLAutolus Therapeutics-$0.26-$0.44-$0.18-$0.44N/AN/A3/6/2024Q4 2023ADAPAdaptimmune Therapeutics-$0.12-$0.24-$0.12-$0.24$4.80 million$0.23 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A2.852.85AUTLAutolus TherapeuticsN/A6.156.15HARPHarpoon TherapeuticsN/A1.891.89PDLIPDL BioPharmaN/AN/AN/ATCRRTCR2 TherapeuticsN/A2.962.96OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%AUTLAutolus Therapeutics72.83%HARPHarpoon Therapeutics74.01%PDLIPDL BioPharmaN/ATCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics18.08%AUTLAutolus Therapeutics25.70%HARPHarpoon Therapeutics17.00%PDLIPDL BioPharma2.20%TCRRTCR2 Therapeutics25.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics449994.21 million814.46 millionOptionableAUTLAutolus Therapeutics463265.93 million197.58 millionOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionablePDLIPDL BioPharma109N/AN/AOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTCRR, PDLI, AUTL, ADAP, and HARP HeadlinesSourceHeadlineTCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatmentpharmaceutical-technology.com - April 17 at 9:14 AMPoseida Therapeutics Inc Ordinary Shares PSTXmorningstar.com - February 25 at 9:43 AMDICE Therapeutics Inc.wsj.com - June 20 at 11:13 PMAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Companyfinance.yahoo.com - June 1 at 4:46 PMTCR2 Therapeutics Insider Trades Send a Signalbenzinga.com - May 16 at 1:36 PMRecap: TCR2 Therapeutics Q1 Earningsmsn.com - May 12 at 9:26 AM10-Q: TCR2 THERAPEUTICS INC.marketwatch.com - May 11 at 11:15 PMTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 11 at 8:13 AMCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Riskyfinance.yahoo.com - April 15 at 12:05 PMMizuho Downgrades Tcr2 Therapeutics (TCRR)msn.com - March 25 at 7:55 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securitiesmarkets.businessinsider.com - March 23 at 7:23 PMAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)markets.businessinsider.com - March 23 at 2:23 PMTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 23 at 9:22 AMTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 23 at 9:22 AMWhat To Know About Jefferies's Downgrade of TCR2 Therapeuticsmsn.com - March 9 at 5:14 PM4 Analysts Have This to Say About TCR2 Therapeuticsmarkets.businessinsider.com - March 9 at 12:14 PMTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwrightmarkets.businessinsider.com - March 8 at 8:52 PMShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmunebenzinga.com - March 6 at 7:17 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyoutbenzinga.com - March 6 at 7:17 PMWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?investorplace.com - March 6 at 12:02 PMTCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinanznachrichten.de - March 6 at 8:28 AMAdaptimmune To Combine With TCR² In All-stock Deal - Quick Factsmarkets.businessinsider.com - March 6 at 8:28 AMAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMAdaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumorsfinance.yahoo.com - March 6 at 8:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdaptimmune TherapeuticsNASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Autolus TherapeuticsNASDAQ:AUTLAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.PDL BioPharmaNASDAQ:PDLIPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.